• Chemogenetic Precision in Translational Neuroscience: Str...

  2025-12-10

  This thought-leadership article explores the mechanistic underpinnings and strategic applications of Clozapine N-oxide (CNO) as a chemogenetic actuator in translational neuroscience. Drawing on recent evidence for cell-type-specific plasticity in somatostatin interneurons, we provide guidance for researchers leveraging CNO to decode neuronal circuits, optimize experimental design, and accelerate clinical translation. The narrative integrates competitive insights, translational relevance for neuropsychiatric models, and a forward-looking vision for chemogenetic innovation.

• Cisapride (R 51619): Nonselective 5-HT4 Agonist & hERG Ch...

  2025-12-09

  Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor used in predictive cardiac electrophysiology research. This compound supports high-content phenotypic screening and is validated for use with iPSC-derived cardiomyocyte models. APExBIO supplies Cisapride (B1198) at high purity, enabling robust interrogation of 5-HT4 signaling and hERG channel inhibition.

• Cisapride (R 51619): Nonselective 5-HT4 Agonist & hERG Ch...

  2025-12-08

  Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor used in cardiac electrophysiology and gastrointestinal motility research. Its high purity and robust documentation make it a reference compound for predictive cardiotoxicity screens. This article details Cisapride's mechanisms, validated benchmarks, and practical integration guidelines for translational workflows.

• Cisapride (R 51619) in Cardiac and Toxicity Assays: Pract...

  2025-12-07

  This article provides an evidence-based, scenario-driven guide for leveraging Cisapride (R 51619) (SKU B1198) in cell viability, proliferation, and cardiotoxicity assays. Addressing real-world laboratory challenges, it demonstrates how high-purity, well-characterized Cisapride from APExBIO supports reproducible workflows, robust data interpretation, and informed product selection for researchers studying 5-HT4 receptor signaling or hERG channel inhibition.

• Cisapride (R 51619): Mechanistic Insights and Strategic G...

  2025-12-06

  Explore how Cisapride (R 51619), a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor, is redefining translational research in cardiac electrophysiology and gastrointestinal motility. This thought-leadership article frames the mechanistic underpinnings, experimental best practices, and strategic opportunities for early-stage drug de-risking—anchored by state-of-the-art phenotypic screening using iPSC-derived cardiomyocytes. Go beyond traditional product summaries and discover actionable guidance for integrating Cisapride into cutting-edge translational workflows.

• Cisapride (R 51619): Reproducible Cardiotoxicity and 5-HT...

  2025-12-05

  This article delivers a scenario-driven, evidence-based exploration of Cisapride (R 51619) (SKU B1198) in cell viability, cytotoxicity, and cardiac electrophysiology assays. It addresses real laboratory challenges—such as compound solubility, assay design, and vendor selection—demonstrating how high-purity Cisapride empowers reproducible, high-content phenotypic screening in modern biomedical research.

• Clozapine N-oxide (CNO): Mechanistic Precision and Strate...

  2025-12-04

  This thought-leadership article explores Clozapine N-oxide (CNO) as a next-generation chemogenetic actuator, integrating mechanistic insights, translational strategy, and clinical context. We synthesize recent scientific findings—including the pivotal role of serotonergic circuits in Alzheimer’s disease-associated depression—while providing actionable guidance for researchers seeking to leverage CNO’s unique properties for reproducible, high-impact neuroscience and GPCR signaling studies. APExBIO’s CNO is spotlighted for its validated reliability and product intelligence, with links to practical protocols and deeper content assets.

• Clozapine N-oxide (CNO): Mechanistic Precision and Strate...

  2025-12-03

  Clozapine N-oxide (CNO), a metabolite of clozapine, is now a cornerstone of modern chemogenetics, enabling precise, reversible, and non-invasive control of neuronal circuits. This thought-leadership article offers mechanistic insights into CNO’s action as a DREADDs activator, critically evaluates its role in translational research—including hypertension and psychiatric disease models—and provides strategic guidance for researchers aiming to leverage this molecule for next-generation neuroscience discoveries. Drawing from recent evidence, including the sympathetic regulation of blood pressure via OVLT activation, and contextualizing CNO’s place in the competitive landscape, the article charts a visionary path for chemogenetic innovation.

• Clozapine N-oxide (CNO): Next-Generation Chemogenetics fo...

  2025-12-02

  This thought-leadership article provides translational researchers with a comprehensive, mechanistic, and strategic roadmap for leveraging Clozapine N-oxide (CNO) in neuroscience. It covers the biological rationale underlying CNO’s chemogenetic specificity, experimental validation through landmark studies, a survey of the evolving competitive landscape, and future directions in clinical and translational neuroscience. Integrating reference findings and broader literature, it positions APExBIO’s CNO as a transformative tool for precise, reversible, and noninvasive neuronal modulation.

• Cisapride (R 51619) in Cardiac and Cell Viability Assays:...

  2025-12-01

  This article delivers an in-depth, scenario-driven analysis of Cisapride (R 51619) (SKU B1198) for cell viability, proliferation, and cardiac electrophysiology research. By illustrating validated lab workflows and data-backed best practices, it guides biomedical researchers in leveraging Cisapride’s high purity, reproducibility, and practical solubility. Each section is grounded in real-world laboratory challenges and references authoritative protocols and supplier comparisons.

• Clozapine N-oxide (CNO): Chemogenetic Actuator for Precis...

  2025-11-30

  Clozapine N-oxide (CNO) is a biologically inert metabolite of clozapine and a gold-standard chemogenetic actuator for DREADDs in neuroscience research. As supplied by APExBIO, CNO enables precise, reversible modulation of neuronal circuits and GPCR signaling with minimal off-target activity.

• Cisapride (R 51619): Unlocking Predictive Cardiotoxicity ...

  2025-11-29

  Explore the multifaceted role of Cisapride (R 51619), a nonselective 5-HT4 receptor agonist and hERG potassium channel inhibitor, in predictive cardiotoxicity and translational research. Discover unique insights into advanced screening strategies, mechanistic applications, and next-generation models that set this analysis apart.

• Clozapine N-oxide (CNO): Reliable Chemogenetic Actuation ...

  2025-11-28

  Discover how Clozapine N-oxide (CNO, SKU A3317) overcomes recurring laboratory challenges in cell viability and neuronal modulation assays. This scenario-driven guide equips biomedical researchers and lab technicians with evidence-based strategies for reproducible, sensitive, and safe chemogenetic workflows using CNO. Leverage data-backed insights to optimize experimental design, data interpretation, and vendor selection.

• Cisapride (R 51619): Nonselective 5-HT4 Agonist and hERG ...

  2025-11-27

  Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor used in cardiac electrophysiology and predictive cardiotoxicity research. High purity, robust solubility in DMSO, and proven utility in iPSC-cardiomyocyte assays make it a reference compound for 5-HT4 signaling and arrhythmia studies.

• Perospirone (SM-9018 Free Base): Atomic Mechanisms in Sch...

  2025-11-26

  Perospirone (SM-9018 free base) is a potent atypical antipsychotic agent for schizophrenia research, acting as a 5-HT2A and D2 antagonist and partial 5-HT1A agonist. Recent studies add Kv1.5 channel inhibition to its mechanistic profile, expanding its utility for neuropsychiatric and cardiovascular disorder models.

15643 records 14/1043 page Previous Next First page 上5页 1112131415 下5页 Last page